Брадиаритмии и нарушения проводимости. Клинические рекомендации 2025

Российское кардиологическое общество

При участии: Ассоциации сердечно-сосудистых хирургов России (АССХ), Всероссийского научного общества специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции (ВНОА)

Одобрено Научно-практическим Советом Минздрава Российской Федерации

1. Howick JH. The Philosophy of Evidence-based Medicine. Wiley.p.15. ISBN: 978-1-4443-4266-6.

2. Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn’t. BMJ. 1996;312:71-2.

3. Андреева Н. С., Реброва О. Ю., Зорин Н. А. Системы оценки достоверности научных доказательств и убедительности рекомендаций: сравнительная характеристика и перспективы унификации. Медицинские технологии. Оценка и выбор. 2012;(4):10-24.

4. Robles de Medina EO, Bernard R, Coumel Ph, et al. Definition of terms related to cardiac rhythm. WHO/ISFC Task Force. Eur J Cardiol. 1978;8:127-44.

5. Егоров Д. Ф., Гордеев О. Л. Диагностика и лечение пациентов с имплантированными антиаритмическими устройствами. СПб.: Человек, 2005. 256 с.

6. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2019;140(8):e382-e482. doi:10.1161/CIR.0000000000000628. Erratum in: Circulation. 2019;140(8):e506-e508. doi:10.1161/CIR.0000000000000721.

7. Brignole M, Auricchio A, Baron-Esquivias G,, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2013;34:2281-329.

8. Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart. 2008;94:1620-6.

9. Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;126:989-96.

10. Perez-Rodon J, Martinez-Alday J, Baron-Esquivias G, et al. Prognostic value of the electrocardiogram in patients with syncope: data from the group for syncope study in the emergency room (GESINUR). Heart Rhythm. 2014;11:2035-44.

11. Thiruganasambandamoorthy V, Hess EP, Turko E, et al. Defining abnormal electrocardiography in adult emergency department syncope patients: the Ottawa Electrocardiographic Criteria. CJEM. 2012;14:248-58.

12. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2017;136:e60-122.

13. Sunjeet S, Marine JE. Evaluating and managing bradycardia. Trends in cardiovascular medicine. 2020;30(5):265-72. doi:10.1016/j.tcm.2019.07.001

14. Бокерия Л. А., Ревишвили А. Ш., Левант А. Д. и др. Рекомендации для имплантации электрокардиостимуляторов при брадикардиях. Кардиология. 1993;33(7):61-9.

15. Chon SB, Kwak YH, Hwang SS, et al. Severe hyperkalemia can be detected immediately by quantitative electrocardiography and clinical history in patients with symptomatic or extreme bradycardia: a retrospective cross-sectional study. J Crit Care. 2013;28:1112.

16. Mandell BF. Cardiovascular involvement in systemic lupus erythematosus. Semin Arthritis Rheum. 1987;17:126-41.

17. Nakayama Y, Ohno M, Yonemura S, et al. A case of transient 2:1 atrioventricular block, resolved by thyroxine supplementation for subclinical hypothyroidism. Pacing Clin Electrophysiol. 2006;29:106-8.

18. Noble K, Isles C. Hyperkalaemia causing profound bradycardia. Heart. 2006;92:1063.

19. Wan D, Blakely C, Branscombe P, et al. Lyme carditis and high-degree atrioventricular block. Am J Cardiol. 2018;121:1102-4.

20. Дроздов Д. В., Макаров Л. М., Баркан В. С. и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023;28(10):5631. doi:10.15829/1560-4071-2023-5631.

21. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2014;127:95.e11-7.

22. Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory electrocardiogram device with a solid-state memory loop. Br Heart J. 1987;58:251-3.

23. Cumbee SR, Pryor RE, Linzer M. Cardiac loop ECG recording: a new noninvasive diagnostic test in recurrent syncope. South Med J. 1990;83:39-43.

24. Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol. 1984;53:1013-7.

25. Joshi AK, Kowey PR, Prystowsky EN, et al. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol. 2005;95:878-81.

26. Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 2: unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med. 1997;127:76-86.

27. Locati ET, Moya A, Oliveira M, et al. External prolonged electrocardiogram monitoring in unexplained syncope and palpitations: results of the SYNARR-Flash study. Europace. 2016;18:1265-72.

28. Reiffel JA, Schwarzberg R, Murry M. Comparison of autotriggered memory loop recorders versus standard loop recorders versus 24-hour Holter monitors for arrhythmia detection. Am J Cardiol. 2005;95:1055-9.

29. Rosenberg MA, Samuel M, Thosani A, et al. Use of a noninvasive continuous monitoring device in the management of atrial fibrillation: a pilot study. Pacing Clin Electrophysiol. 2013;36:328-33.

30. Rothman SA, Laughlin JC, Seltzer J, et al. The diagnosis of cardiac arrhythmias: a prospective multi-center randomized study comparing mobile cardiac outpatient telemetry versus standard loop event monitoring. J Cardiovasc Electrophysiol. 2007;18:241-7.

31. Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders versus Holter monitors in patients with syncope or presyncope. Am J Med. 2003;115:1-5.

32. Turakhia MP, Hoang DD, Zimetbaum P, et al. Diagnostic utility of a novel leadless arrhythmia monitoring device. Am J Cardiol. 2013;112:520-4.

33. Мацкеплишвили С. Т., Саидова М. А., Мироненко М. Ю. и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025;30(2):6271. doi:10.15829/1560-4071-2025-6271. EDN: TNLDFN.

34. Ревишвили А. Ш., Бойцов С. А., Давтян К. В. и др. Клинические рекомендации по проведению электрофизиологических исследований, катетерной абляции и применению имплантируемых антиаритмических устройств. М.: 2017. 702 с.

35. Dagres N, Bongiorni MG, Dobreanu D, et al. Current investigation and management of patients with syncope: results of the European Heart Rhythm Association survey. Europace. 2013;15:1812-5.

36. Schneider JF, Thomas HE Jr, Kreger BE, et al. Newly acquired left bundle-branch block: the Framingham study. Ann Intern Med. 1979;90:303-10.

37. Schneider JF, Thomas HE Jr, Sorlie P, et al. Comparative features of newly acquired left and right bundle branch block in the general population: the Framingham study. Am J Cardiol. 1981;47:931-40.

38. Talreja D, Gruver C, Sklenar J, et al. Efficient utilization of echocardiography for the assessment of left ventricular systolic function. Am Heart J. 2000;139:394-8.

39. Dhingra R, Ho Nam B, Benjamin EJ, et al. Cross-sectional relations of electrocardiographic QRS duration to left ventricular dimensions: the Framingham Heart Study. J Am Coll Cardiol. 2005;45:685-9.

40. Dhingra R, Pencina MJ, Wang TJ, et al. Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. Hypertension. 2006;47:861-7.

41. Badheka AO, Singh V, Patel NJ, et al. QRS duration on electrocardiography and cardiovascular mortality (from the National Health and Nutrition Examination Survey-III). Am J Cardiol. 2013;112:671-7.

42. Bogale N, Orn S, James M, et al. Usefulness of either or both left and right bundle branch block at baseline or during follow-up for predicting death in patients following acute myocardial infarction. Am J Cardiol. 2007;99:647-50.

43. Eriksson P, Hansson PO, Eriksson H, et al. Bundle-branch block in a general male population: the study of men born 1913. Circulation. 1998;98:2494-500.

44. Fahy GJ, Pinski SL, Miller DP, et al. Natural history of isolated bundle branch block. Am J Cardiol. 1996;77:1185-90.

45. Imanishi R, Seto S, Ichimaru S, et al. Prognostic significance of incident complete left bundle branch block observed over a 40-year period. Am J Cardiol. 2006;98:644-8.

46. Chiu DT, Shapiro NI, Sun BC, et al. Are echocardiography, telemetry, ambulatory electrocardiography monitoring, and cardiac enzymes in emergency department patients presenting with syncope useful tests? A preliminary investigation. J Emerg Med. 2014;47:113-8.

47. Douglas PS, Garcia MJ, Haines DE, et al. ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/ SCCM/SCCT/SCMR. 2011 Аppropriate use criteria for echocardiography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance American College of Chest Physicians. J Am Soc Echocardiogr. 2011;24:229-67.

48. Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. Am J Cardiol. 1998;82:1205-9.

49. Bluemke DA, Achenbach S, Budoff M, et al. Noninvasive coronary artery imaging: magnetic resonance angiography and multidetector computed tomography angiography: a scientific statement from the american heart association committee on cardiovascular imaging and intervention of the council on cardiovascular radiology and intervention, and the councils on clinical cardiology and cardiovascular disease in the young. Circulation. 2008;118:586-606.

50. Bokhari S, Castano A, Pozniakoff T, et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195-201.

51. Cheong B, Huber S, Muthupillai R, et al. Evaluation of myocardial iron overload by T(2)* cardiovascular magnetic resonance imaging. Tex Heart Inst J. 2005;32:448-9.

52. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570-9.

53. Franco A, Javidi S, Ruehm SG. Delayed myocardial enhancement in cardiac magnetic resonance imaging. J Radiol Case Rep. 2015;9:6-18.

54. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501-11.

55. Haq M, Pawar S, Berk JL, et al. Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging. 2017;10:713-4.

56. Taylor AJ, Cerqueira M, Hodgson JM, et al. ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/ SCAI/SCMR 2010 appropriate use criteria for cardiac computed tomography: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the Society of Cardiovascular Computed Tomography, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the American Society of Nuclear Cardiology, the North American Society for Cardiovascular Imaging, the Society for Cardiovascular Angiography and Interventions, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2010;122:e525-55.

57. Halliday BP, Gulati A, Ali A, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135:2106-15.

58. Kazmirczak F, Chen KA, Adabag S, et al. Assessment of the 2017 AHA/ACC/HRS Guideline Recommendations for Implantable Cardioverter-Defibrillator Implantation in Cardiac Sarcoidosis. Circ Arrhythm Electrophysiol. 2019;12:e007488.

59. Aquaro GD, Perfetti M, Camastra G, et al. Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol. 2017;70:1977-87.

60. Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72:3158-76.

61. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol. 2011;4:303-9.

62. Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. Arch Intern Med. 2009;169:1299-305.

63. Recchia D, Barzilai B. Echocardiography in the evaluation of patients with syncope. J Gen Intern Med. 1995;10:649-55.

64. Tilkian AG, Guilleminault C, Schroeder JS, et al. Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. Am J Med. 1977;63:348-58.

65. Guilleminault C, Connolly SJ, Winkle RA. Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. Am J Cardiol. 1983;52:490-4.

66. Shepard JW Jr, Garrison MW, Grither DA, et al. Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. Chest. 1985;88:335-40.

67. Shepard JW Jr. Gas exchange and hemodynamics during sleep. Med Clin North Am. 1985;69:1243-64.

68. Hoffstein V, Mateika S. Cardiac arrhythmias, snoring, and sleep apnea. Chest. 1994;106: 466-71.

69. Boudoulas H, Schmidt HS, Clark RW, et al. Anthropometric characteristics, cardiac abnormalities and adrenergic activity in patients with primary disorders of sleep. J Med. 1983;14:223-38.

70. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleepdisordered breathing: The Sleep Heart Health Study. Am J Respir Crit Care Med. 2006;173:910-6.

71. Miller WP. Cardiac arrhythmias and conduction disturbances in the sleep apnea syndrome. Prevalence and significance. Am J Med. 1982;73:317-21.

72. Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac arrhythmias. Is there a relationship? Am Rev Respir Dis. 1993;148:618-21.

73. Stegman SS, Burroughs JM, Henthorn RW. Asymptomatic bradyarrhythmias as a marker for sleep apnea: appropriate recognition and treatment may reduce the need for pace-maker therapy. Pacing Clin Electrophysiol. 1996;19:899-904.

74. Garrigue S, Pepin JL, Defaye P, et al. High prevalence of sleep apnea syndrome in patients with long-term pacing: the European Multicenter Polysomnographic Study. Circulation. 2007;115:1703-9.

75. Becker H, Brandenburg U, Peter JH, et al. Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. Am J Respir Crit Care Med. 1995;151:215-8.

76. Koehler U, Fus E, Grimm W, et al. Heart block in patients with obstructive sleep apnoea: pathogenetic factors and effects of treatment. Eur Respir J. 1998;11:434-9.

77. Grimm W, Koehler U, Fus E, et al. Outcome of patients with sleep apnea-associated severe bradyarrhythmias after continuous positive airway pressure therapy. Am J Cardiol. 2000;86:688-92.

78. Harbison J, O’Reilly P, McNicholas WT. Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. Chest. 2000;118:591-5.

79. Daccarett M, Segerson NM, Hamdan AL, et al. Relation of daytime bradyarrhythmias with high risk features of sleep apnea. Am J Cardiol. 2008;101:1147-50.

80. Grimm W, Hoffmann J, Menz V, et al. Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. Am J Cardiol. 1996;77:1310-4.

81. Guilleminault C, Pool P, Motta J, Gillis AM. Sinus arrest during REM sleep in young adults. N Engl J Med. 1984;311:1006-10.

82. Simantirakis EN, Schiza SI, Marketou ME, et al. Severe bradyarrhythmias in patients with sleep apnoea: the effect of continuous positive airway pressure treatment: a long-term evaluation using an insertable loop recorder. Eur Heart J. 2004;25:1070-6.

83. Brubaker H. and Kitzman D W. Chronotropic Incompetence: Causes, Consequences, and Management. Circulation. 2011;123:1010-20.

84. Melzer Ch, Dreger H. Chronotropic incompetence: a never-ending story. Europace. 2010;12:464-5.

85. Adornato E, Adornato EMF. Chronotropic Incompetence: How to Diagnose and Treat It? In: Raviele A. (eds) Cardiac Arrhythmias 1997. Springer, Milano. doi:10.1007/978-88-470-2288-1_62.

86. Savonen KP, Kiviniemi V, Laukkanen JA, et al. Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart disease. Eur Heart J. 2008;29:1896-902.

87. Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). Arch Cardiovasc Dis. 2014;107:546-52.

88. Woelfel AK, Simpson RJ Jr, Gettes LS, Foster JR. Exercise-induced distal atrioventricular block. J Am Coll Cardiol. 1983;2:578-81.

89. Byrne JM, Marais HJ, Cheek GA. Exercise-induced complete heart block in a patient with chronic bifascicular block. J Electrocardiol. 1994;27:339-42.

90. Aste M, Oddone D, Donateo P, et al. Syncope in patients paced for atrioventricular block. Europace. 2016;18:1735-9.

91. Sumiyoshi M, Nakata Y, Yasuda M, et al. Clinical and electrophysiologic features of exercise-induced atrioventricular block. Am Heart J. 1996;132:1277-81.

92. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39:1883-948.

93. Ommen SR, Nishimura RA, Squires RW, et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol. 1999;34:191-6.

94. Gibbons CH, Freeman R. Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance. Neurology. 2006;67:28-32.

95. Kenny RA, Ingram A, Bayliss J, Sutton R. Head-up tilt: a useful test for investigating unexplained syncope. Lancet. 1986;1:1352-5.

96. Bartoletti A, Alboni P, Ammirati F, et al. ‘The Italian Protocol‘: a simplified head-up tilt testing potentiated with oral nitroglycerin to assess patients with unexplained syncope. Europace. 2000;2:339-42.

97. Kenny RA, O’Shea D, Parry SW. The Newcastle protocols for head-up tilt table testing in the diagnosis of vasovagal syncope, carotid sinus hypersensitivity, and related disorders. Heart. 2000;83:564-9.

98. Benditt DG, Ferguson DW, Grubb BP, et al. Tilt table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol. 1996;28:263-75.

99. Morillo CA, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a low-dose isoproterenol head-up tilt protocol. Am Heart J. 1995;129:901-6.

100. Parry SW, Gray JC, Newton JL, et al. ‘Front-loaded‘ head-up tilt table testing: validation of a rapid first line nitrate-provoked tilt protocol for the diagnosis of vasovagal syncope. Age Ageing. 2008;37:411-5.

101. Verheyden B, Gisolf J, Beckers F, et al. Impact of age on the vasovagal response provoked by sublingual nitroglycerine in routine tilt testing. Clin Sci (Lond). 2007;113:329-37.

102. Nilsson D, Sutton R, Tas W, et al. Orthostatic changes in hemodynamics and cardiovascular biomarkers in dysautonomic patients. PLoS One. 2015;10:e0128962.

103. Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20:352-8.

104. Petersen ME, Williams TR, Sutton R. Psychogenic syncope diagnosed by prolonged head-up tilt testing. QJM. 1995;88:209-13.

105. Tannemaat MR, van Niekerk J, Reijntjes RH, et al. The semiology of tilt-induced psychogenic pseudosyncope. Neurology. 2013;81:752-8.

106. Blad H, Lamberts RJ, van Dijk GJ, Thijs RD. Tilt-induced vasovagal syncope and psychogenic pseudosyncope: Overlapping clinical entities. Neurology. 2015;85:2006-10.

107. Moya A., Alonso C. Tilt-induced syncope: purely vasodepressor response. In: Syncope cases. R. Garsia-Civera, G. Bar on-Esquias, J. Blanc, A. Moya, R. Ruiz-Granell, W. Wieling (eds). Blackwell publ, 2006;21-4.

108. Wissocq L, Ennezat PV, Mouquet F. Exercise-induced high-degree atrioventricular block. Arch Cardiovasc Dis. 2009;102:733-5.

109. Solari D, Maggi R, Oddone D, et al. Assessment of the vasodepressor reflex in carotid sinus syndrome. Circ Arrhythm Electrophysiol. 2014;7:505-10.

110. Solari D, Maggi R, Oddone D, et al. Clinical context and outcome of carotid sinus syndrome diagnosed by means of the ‘method of symptoms’. Europace. 2014;16:928-34.

111. Brignole M, Ungar A, Casagranda I, et al., Syncope Unit Project (SUP) investigators. Prospective multicenter systematic guideline-based management of patients referred to the Syncope Units of general hospitals. Europace. 2010;12:109-18.

112. Linde C, Gadler F, Kappenberger L, Ryden L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. 1999;83:903-7.

113. Brady WJ, Swart G, DeBehnke DJ, et al. The efficacy of atropine in the treatment of hemodynamically unstable bradycardia and atrioventricular block: prehospital and emergency department considerations. Resuscitation. 1999;41:47-55.

114. Liu P, Zhou Y-F, Yang P, et al. Optimized axillary vein technique versus subclavian vein technique in cardiovascular implantable electronic device implantation. Chin Med J. 2016;129:2647-51.

115. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Pneumothorax in cardiac pacing: a population-based cohort study of 28860 Danish patients. Europace. 2012;14:1132-8.

116. Warren JV, Lewis RP. Beneficial effects of atropine in the pre-hospital phase of coronary care. Am J Cardiol. 1976;37:68-72.

117. Дорошенко Д. И., Илюхин О. В., Пром А. К., Иваненко В. В. Основы электрокардиографической диагностики нарушений ритма сердца: учебное пособие. Волгоград: Изд-во ВолгГМУ, 2022. 68 с.

118. Rishniw M; Tobias, AH; Slinker BK. Characterization of chronotropic and dysrhythmogenic effects of atropine in dogs with bradycardia. Am J Vet Res. 1996;57(3):337-34.

119. Rishniw M, Kittleson MD, Jaffe RS, Kass PH. Characterization of parasympatholytic chronotropic responses following intravenous administration of atropine to clinically normal dogs. Am J Vet Res. 1999;60:1000-3.

120. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Heart Rhythm. 2011;8:1308-39.

121. Ishikawa T, Tsuji Y, Makita N. Inherited bradyarrhythmia: a diverse genetic background. J Arrhythm. 2016;32:352-8.

122. Smits JP, Veldkamp MW, Wilde AA. Mechanisms of inherited cardiac conduction disease. Europace. 2005;7:122-37.

123. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932-63.

124. Da Costa A, Defaye P, Romeyer-Bouchard C, et al. Clinical impact of the implantable loop recorder in patients with isolated syncope, bundle branch block and negative work-up: a randomized multicentre prospective study. Arch Cardiovasc Dis. 2013;106:146-54.

125. Megevand A, Ingles J, Richmond DR, Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am J Cardiol. 2005;95:991-3.

126. Sulke N, Sugihara C, Hong P, et al. The benefit of a remotely monitored implantable loop recorder as a first line investigation in unexplained syncope: the EaSyAS II trial. Europace. 2016;18:912-8.

127. Morise А. Exercise Testing in Nonatherosclerotic Heart Disease, Hypertrophic Cardiomyopathy, Valvular Heart Disease, and Arrhythmias. Circulation. 2011;123: 216-25.

128. Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J. 2004;25:1257-63.

129. Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation. 2001;104:46-51.

130. Krahn AD, Klein GJ, Yee R, et al. Final results from a pilot study with an implantable loop recorder to determine the etiology of syncope in patients with negative noninvasive and invasive testing. American Journal of Cardiology. 1998;82:A8-A9.

131. Sommer A, Kronborg MB, Norgaard BL, et al. Left and right ventricular lead positions are imprecisely determined by fluoroscopy in cardiac resynchronization therapy: a comparison with cardiac computed tomography. Europace. 2014;16:1334-41.

132. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11:671-87.

133. Assar M, Krahn A, Klein G, Yee R, Skanes A. Optimal duration of monitoring in patients with unexplained syncope. Am J Cardiol. 2003;92:1231-123.

134. Farwell D, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J. 2006;27:351-6.

135. Brignole M, Sutton R, Menozzi C, et al.; International Study on Syncope of Uncertain Etiology 2 (ISSUE2) Group. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J. 2006;27:1085-92.

136. Brignole M, Menozzi C, Maggi R, et al. The usage and diagnostic yield of the implantable loop recorder in detection of the mechanism of syncope and in guiding effective antiarrhythmic therapy in older people. Europace. 2005;7:273-9.

137. Krahn AD, Klein GJ, Yee R, et al. Cost implications of testing strategy in patients with syncope: randomized assessment of syncope trial. J Am Coll Cardiol. 2003;42(3):495-501.

138. Solano A, Menozzi C, Maggi R, et al. Incidence, diagnostic yield and safety of the implantable looprecorder to detect the mechanismof syncope in patients with and without structural heart disease. Eur Heart J. 2004;25:1116-9.

139. Burri H, Starck C, Auricchio A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 2021;1-26. doi:10.1093/europace/euaa367.

140. Furukawa T, Maggi R, Bertolone C, et al. Additional diagnostic value of very prolonged observation by implantable loop recorder in patients with unexplained syncope. J Cardiovasc Electrophysiol. 2012;23(1):67-71. doi:10.1111/j.1540-8167.2011.02133.x.

141. Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS); Moya A, Sutton R, Ammirati F, et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30(21):2631-71. doi:10.1093/eurheartj/ehp298.

142. Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol. 2000;36:181-4.

143. Brignole M, Menozzi C, Moya A, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation. 2001;104:2045-50.

144. Menozzi C, Brignole M, Garcia-Civera R, et al. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation. 2002;105:2741-5.

145. DiMarco JP, Garan H, Ruskin JN. Approach to the patient with recurrent syncope of unknown cause. Mod Concepts Cardiovasc Dis. 1983;52:11-6.

146. Fisher JD. Role of electrophysiologic testing in the diagnosis and treatment of patients with known and suspected bradycardias and tachycardias. Prog Cardiovasc Dis. 1981;24: 25-90.

147. Gulamhusein S, Naccarelli GV, Ko PT, et al. Value and limitations of clinical electrophysiologic study in assessment of patients with unexplained syncope. Am J Med. 1982;73:A53.

148. Krol RB, Morady F, Flaker GC, et al. Electrophysiologic testing in patients with unexplained syncope: clinical and noninvasive predictors of outcome. J Am Coll Cardiol. 1987;10:358-63.

149. Denniss AR, Ross DL, Richards DA, et al. Electrophysiologic studies in patients with unexplained syncope. Int J Cardiol. 1992;35:211-7.

150. Руководство по экстракции электродов имплантируемых электронных устройств — показания, методики, оснащение, ведение пациентов. Под редакцией Ревишвили А. Ш., Айвазьян С. А., Артюхина Е. А. и др. Видар. 2021. ISBN: 978-5-88429-268-0.

151. Altschuler H, Fisher JD, Furman S. Significance of isolated H-V interval prolongation in symptomatic patients without documented heart block. Am Heart J. 1979;97:19-26.

152. Fujimura O, Yee R, Klein GJ, et al. The diagnostic sensitivity of electrophysiologic testing inpatients with syncope caused by transient bradycardia. N Engl J Med. 1989;321:1703-7.

153. Strauss HC, Bigger JT Jr, Saroff AL, Giardina EG. Electrophysiologic evaluation of sinus node function in patients with sinus node dysfunction. Circulation. 1976;53:763-76.

154. Strauss HC, Saroff AL, Bigger JT Jr, Giardina EG. Premature atrial stimulation as a key to the understanding of sinoatrial conduction in man: presentation of data and critical review of the literature. Circulation. 1973;47:86-93.

155. Breithardt G, Seipel L, Loogen F. Sinus node recovery time and calculated sinoatrial conduction time in normal subjects and patients with sinus node dysfunction. Circulation. 1977;56:43-50.

156. Gann D, Tolentino A, Samet P. Electrophysiologic evaluation of elderly patients with sinus bradycardia: a long-term follow-up study. Ann Intern Med. 1979;90:24-9.

157. Damato AN, Lau SH, Helfant R, et al. A study of heart block in man using His bundle recordings. Circulation 1969;39:297-305.

158. Faster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in col-laboration with the North American Society of Pacing and Electrophysiology. Circulation. 2001;104:2118-50.

159. Scheinman MM, Huang S. The 1998 NASPE prospective catheter ablation registry. Pacing Clin Electrophysiol. 2000;23:1020-8.

160. Crawford MH, Bernstein SJ, Deedwania PC et al. ACC/AHA guidelines for ambulatory electrocardiography: executive summary and recommendations, a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Circulation. 1999;100:886-93.

161. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia Circulation. 2016;133(14):e506-74. doi:10.1161/CIR.0000000000000311. Erratum in: Circulation. 2016;134(11):e234-5. doi:10.1161/CIR.0000000000000448.

162. Jackson LR 2nd, Rathakrishnan B, Campbell K, et al. Sinus node dysfunction and atrial fibrillation: a reversible phenomenon? Pacing Clin Electrophysiol. 2017;40:442-50.

163. McAnulty JH, Rahimtoola SH, Murphy E, et al. Natural history of ‘high-risk’ bundle-branch block: final report of a prospective study. N Engl J Med. 1982;307:137-43.

164. Gronda M, Magnani A, Occhetta E, et al. Electrophysiological study of atrio-ventricular block and ventricular conduction defects. Prognostic and therapeutical implications. G Ital Cardiol. 1984;14:768-73.

165. Bergfeldt L, Edvardsson N, Rosenqvist M, et al. Atrioventricular block progression in patients with bifascicular block assessed by repeated electrocardiography and a bradycardia-detecting pacemaker. Am J Cardiol. 1994;74:1129-32.

166. Kaul U, Dev V, Narula J, et al. Evaluation of patients with bundle branch block and ‘unex-plained’ syncope: a study based on comprehensive electrophysiologic testing and ajmaline stress. Pacing Clin Electrophysiol. 1988;11:289-97.

167. Moya A, Garcia-Civera R, Croci F, et al. Diagnosis, management, and outcomes of patients with syncope and bundle branch block. Eur Heart J. 2011;32:1535-41.

168. Twidale N, Heddle WF, Tonkin AM. Procainamide administration during electrophysiology study — utility as a provocative test for intermittent atrioventricular block. Pacing Clin Electrophysiol. 1988;11:1388-97.

169. Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99:2927-33.

170. Ogawa H, Inoue T, Miwa S, et al. Heart rate responses to autonomic drugs in sick sinus syndrome — correlation with syncope and electrophysiologic data. Jpn Circ J. 1991;55:15-23.

171. Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency department. Resuscitation. 2007;73:96-102.

172. Strauss, H.C., Bigger, J.T.: Electrophysiological properties of the rabbit sinoatrial perinodal fibers. Circulation Res. 1972;31:490.

173. Aghamohammadi H, Mehrabi S, Mohammad Ali Beigi F. Prevention of bradycardia by atropine sulfate during urological laparoscopic surgery: a randomized controlled trial. Urol J. 2009;6:92-5.

174. Grmec S, Strnad M, Podgorsek D. Comparison of the characteristics and outcome among patients suffering from out-of-hospital primary cardiac arrest and drowning victims incardiac arrest. Int J Emerg Med. 2009;2:7-12.

175. Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect. 2000;6:633-4.

176. Herman SC, Zhou J. Isoproterenol infusion for treatment of refractory symptomatic bradycardia in parturients with congenital complete heart block. Int J Obstet Anesth. 2011;20:361-3; author reply 3.

177. Mandel WJ, Hayakawa H, Allen HN, et al. Assessment of sinus node function in patients with the sick sinus syndrome. Circulation. 1972;46:761-9.

178. Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing versus conventional treatment: "PrePACE". Resuscitation. 2008;76:341-9.

179. Bernheim A, Fatio R, Kiowski W, et al. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. Transplantation. 2004;77:1181-5.

180. Link MS, Berkow LC, Kudenchuk PJ, et al. Part 7: adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:444-64.

181. Dhingra RC, Deedwania PC, Cummings JM, et al. Electrophysiologic effects of lidocaine on sinus node and atrium in patients with and without sinoatrial dysfunction. Circulation. 1978;57:448-54.

182. Meyer EC, Sommers DK, Schoeman HS, et al. The effect of atropine on heart-rate: a comparison between two ethnic groups. Br J Clin Pharmacol. 1988;25:776-7.

183. Feigl D, Ashkenazy J, Kishon Y. Early and late atrioventricular block in acute inferior myocardial infarction. J Am Coll Cardiol. 1984;4:35-8.

184. Hu F, Zheng L, Liang E, et al. Right anterior ganglionated plexus: the primary target of cardioneuroablation? Heart Rhythm. 2019;16(10):1545-51.

185. Chihrin SM, Mohamed U, Yee R, et al. Utility of isoproterenol in unmasking latent escape rhythm in pacemaker dependent patients undergoing pacemaker replacement. Am J Cardiol. 2008;101:631-3.

186. Dhingra RC, Winslow E, Pouget JM, et al. The effect of isoproterenol on atrioventricularand intraventricular conduction. Am J Cardiol. 1973;32:629-36.

187. Hatle L, Rokseth R. Conservative treatment of AV block in acute myocardial infarction. Results in 105 consecutive patients. Br Heart J. 1971;33:595-600.

188. Сергуладзе С. Ю., Артюхина Е. А., Кваша Б. И. и др. Отдаленные результаты имплантации эпикардиальных стероидных электродов после хирургического удаления эндокардиальных электродов у пациента с септическим электродным эндокардитом. Вестник аритмологии. 2016;(83):81-3.

189. Hedges JR, Feero S, Shultz B, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia. Pacing Clin Electrophysiol. 1991;14:1473-8.

190. Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: a diagnostic and therapeutic tool. Circulation. 1982;65:336-41.

191. Smith I, Monk TG, White PF. Comparison of transesophageal atrial pacing with anticholinergic drugs for the treatment of intraoperative bradycardia. Anesth Analg. 1994;78:245-52.

192. Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc. 1983;58:122-6.

193. Tjong FVY, de Ruijter UW, Beurskens NEG, Knops RE. A comprehensive scoping review on transvenous temporary pacing therapy. Neth Heart J. 2019;27:462-73.

194. Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation. 2006;70:193-200.

195. Kappenberger L, Linde C, Daubert C, et al. Pacing in hypertrophic obstructive cardiomyopathy: a randomized crossover study. Eur Heart J. 1997;18:1249-56.

196. Quast ABE, Beurskens NEG, Ebner A, et al. Feasibility of an entirely extracardiac, minimally invasive, temporary pacing system. Circ Arrhythm Electrophysiol. 2019;12:e007182.

197. López Ayerbe J, VilluendasSabaté R, García García C, et al. Temporary pacemakers: current use and complications. Revista Española de Cardiología (Engl Ed). 2004;57:1045-52.

198. Bjornstad CC, Gjertsen E, Thorup F, et al. Temporary cardiac pacemaker treatment in five Norwegian regional hospitals. Scand Cardiovasc J. 2012;46:137-43.

199. Murphy JJ. Current practice and complications of temporary transvenous cardiac pacing. BMJ. 1996;312:1134.

200. Lever N, Ferguson JD, Bashir Y, et al. Prolonged temporary cardiac pacing using subcutaneous tunnelled active-fixation permanent pacing leads. Heart. 2003;89:209-10.

201. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767-77.

202. Rastan AJ, Doll N, Walther T, Mohr FW. Pacemaker dependent patients with device infection — a modified approach. Eur J Cardiothorac Surg. 2005;27:1116-8.

203. Nishimura RA, Trusty JM, Hayes DL, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29:435-41.

204. Weinstein J, Gnoj J, Mazzara JT, et al. Temporary transvenous pacing via the percutaneous femoral vein approach. A prospective study of 100 cases. Am Heart J. 1973;85:695-705.

205. Bektas F, Soyuncu S. The efficacy of transcutaneous cardiac pacing in ED. Am J Emerg Med. 2016;34:2090-3.

206. Clinton JE, Zoll PM, Zoll R, et al. Emergency noninvasive external cardiac pacing. J Emerg Med. 1985;2:155-62.

207. Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. Circulation. 1985;71:937-44.

208. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for devicebased therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350-408.

209. Silver MD, Goldschlager N. Temporary transvenous cardiac pacing in the critical care setting. Chest. 1988;93:607-13.

210. McLeod AA, Jokhi PP. Pacemaker induced ventricular fibrillation in coronary care units. BMJ. 2004;328:1249-50.

211. Braun MU, Rauwolf T, Bock M, et al. Percutaneous lead implantation connected to an external device in stimulation-dependent patients with systemic infection — a prospective and controlled study. Pacing Clin Electrophysiol. 2006;29:875-9.

212. Pachon-M EI, Pachon-Mateos JC, Higuti C, et al. Relation of Fractionated Atrial Potentials With the Vagal Innervation Evaluated by Extracardiac Vagal Stimulation During Cardioneuroablation. Circ Arrhythm Electrophysiol. 2020;13(4):e007900. doi:10.1161/CIRCEP.119.007900.

213. Piotrowski R., Baran J., Sikorska A., et al. Cardioneuroablation for reflex syncope: efficacy and effects on autonomic cardiac regulation-a prospective randomized trial. JACC Clin. Electrophysiol. 2023;9(1):85.

214. El Iskandarani M., Golamari R., Shatla I., et al. Left bundle branch area pacing in heart failure: a systematic review and meta-analysis with meta-regression. J. Cardiovasc. Electrophysiol. 2024;35(8):1536-47.

215. Lang R, David D, Klein HO, et al. The use of the balloon-tipped floating catheter in temporary transvenous cardiac pacing. Pacing Clin Electrophysiol. 1981;4:491-6.

216. Segreti L, Rinaldi CA, Claridge S, et al. Procedural outcomes associated with transvenous lead extraction in patients with abandoned leads: an ESC-EHRA ELECTRa (European Lead Extraction ConTRolled) registry sub-analysis. Europace. 2019;21:645-54.

217. Chihrin SM, Mohammed U, Yee R, et al. Utility and cost effectiveness of temporary pacing using active fixation leads and an externally placed reusable permanent pacemaker. Am J Cardiol. 2006;98:1613-5.

218. De Cock CC, Van Campen CM, In’t Veld JA, et al. Utility and safety of prolonged temporary transvenous pacing using an active-fixation lead: comparison with a conventional lead. Pacing Clin Electrophysiol. 2003;26:1245-8.

219. Kawata H, Pretorius V, Phan H, et al. Utility and safety of temporary pacing using active fixation leads and externalized re-usable permanent pacemakers after lead extraction. Europace. 2013;15:1287-91.

220. Kornberger A, Schmid E, Kalender G, et al. Bridge to recovery or permanent system implantation: an eight-year single-center experience in transvenous semipermanent pacing. Pacing Clin Electrophysiol. 2013;36:1096-103.

221. Zei PC, Eckart RE, Epstein LM. Modified temporary cardiac pacing using transvenous active fixation leads and external re-sterilized pulse generators. J Am Coll Cardiol. 2006;47:1487-9.

222. Hwang YM, Kim CM, Moon KW. Periprocedural temporary pacing in primary percutaneous coronary intervention for patients with acute inferior myocardial infarction. Clin Interv Aging. 2016;11:287-92.

223. Bocka JJ. External transcutaneous pacemakers. Ann Emerg Med. 1989;18:1280-6. doi:10.1016/s0196-0644(89)80259-8.

224. Sharma AD, Rizo-Patron C, Hallstrom AP, et al. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005;2:830-4.

225. Sweeney MO, Prinzen FW. A new paradigm for physiologic ventricular pacing. J Am Coll Cardiol. 2006;47:282-8.

226. Alboni P, Menozzi C, Brignole M, et al. Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a randomized controlled trial. Circulation. 1997;96:260-6.

227. Saito D, Matsubara K, Yamanari H, et al. Effects of oral theophylline on sick sinus syndrome. J Am Coll Cardiol. 1993;21:1199-204.

228. Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282-93.

229. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240-327.

230. Gauss A, Hubner C, Meierhenrich R, et al. Perioperative transcutaneous pacemaker in patients with chronic bifascicular block or left bundle branch block and additional first-degree atrioventricular block. Acta Anaesthesiol Scand. 1999;43:731-6.

231. Im SH, Han MH, Kim SH, et al. Transcutaneous temporary cardiac pacing in carotid stenting: noninvasive prevention of angioplastyinduced bradycardia and hypotension. J Endovasc Ther. 2008;15:110-6.

232. Marrocco-Trischitta MM, Mazzone P, Vitale R, et al. Temporary transvenous pacemaker implantation during carotid endarterectomy in patients with trifascicular block. Ann Vasc Surg. 2016;34:206-11.

233. Morris D, Mulvihill D, Lew WY. Risk of developing complete heart block during bedside pulmonary artery catheterization in patients with left bundle-branch block. Arch Intern Med. 1987;147:2005-10.

234. Unnikrishnan D, Idris N, Varshneya N. Complete heart block during central venous catheter placement in a patient with pre-existing left bundle branch block. Br J Anaesth. 2003;91:747-9.

235. Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) registry of transvenous lead extraction outcomes. Eur Heart J. 2017;38:2995-3005.

236. Dhingra RC, Denes P, Wu D, et al. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block. Circulation. 1974;49:638-46.

237. Ector H, Rolies L, De Geest H. Dynamic electrocardiography and ventricular pauses of 3 seconds and more: etiology and therapeutic implications. Pacing Clin Electrophysiol. 1983;6:548-51.

238. Edhag O, Swahn A. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A long-term follow-up study of 101 patients. Acta Med Scand. 1976;200:457-63.

239. Shaw DB, Eraut D. Prevalence and morbidity of heart block in Devon. Br Med J. 1970;1:144-7.

240. Andersen HR, Nielsen JC, Thomsen PE, et al. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome. Lancet. 1997;350:1210-6.

241. Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med. 2000;342:1385-91.

242. Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med. 2002;346:1854-62.

243. Lamas GA, Orav EJ, Stambler BS, et al. Quality of life and clinical outcomes in elderly patients treated with ventricular pacing as compared with dual-chamber pacing. Pacemaker Selection in the Elderly Investigators. N Engl J Med. 1998;338:1097-104.

244. Brandt NH, Kirkfeldt RE, Nielsen JC, et al. Single lead atrial vs. dual chamber pacing in sick sinus syndrome: extended register-based follow-up in the DANPACE trial. Europace. 2017;19(12):1981-7. doi:10.1093/europace/euw364.

245. Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007;357:1000-8.

246. Gillis AM, Russo AM, Ellenbogen KA, et al. HRS/ACCF expert consensus statement on pacemaker device and mode selection. J Am Coll Cardiol. 2012;60:682-703.

247. Dretzke J, Toff WD, Lip GY, et al. Dual chamber versus single chamber ventricular pace-makers for sick sinus syndrome and atrioventricular block. Cochrane Database Syst Rev. 2004; CD003710.

248. Andersen HR, Nielsen JC, Thomsen PE, et al. Atrioventricular conduction during long-term follow-up of patients with sick sinus syndrome. Circulation. 1998;98:1315-21.

249. Brandt J, Anderson H, Fahraeus T, et al. Natural history of sinus node disease treated with atrial pacing in 213 patients: implications for selection of stimulation mode. J Am Coll Cardiol. 1992;20:633-9.

250. Auricchio A, Ellenbogen KA. Reducing ventricular pacing frequency in patients with atrioventricular block: is it time to change the current pacing paradigm? Circ Arrhythm Electrophysiol. 2016;9:e004404.

251. Stockburger M, Boveda S, Moreno J, et al. Long-term clinical effects of ventricular pacing reduction with a changeover mode to minimize ventricular pacing in a general pacemaker population. Eur Heart J. 2015;36:151-7.

252. Boriani G, Tukkie R, Manolis AS, et al., MINERVA Investigators. Atrial antitachycardia pacing and managed ventricular pacing in bradycardia patients with paroxysmal or persistent atrial tachyarrhythmias: the MINERVA randomized multicentre international trial. Eur Heart J. 2014;35:2352-62.

253. Stockburger M, Gomez-Doblas JJ, Lamas G, et al. Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail. 2011;13:633-41.

254. Stockburger M, Defaye P, Boveda S, et al. Safety and efficiency of ventricular pacing prevention with an AAI-DDD changeover mode in patients with sinus node disease or atrioventricular block: impact on battery longevity — a sub-study of the ANSWER trial. Europace. 2016;18:739-46.

255. Thibault B, Simpson C, Gagne CE, et al. Impact of AV conduction disorders on SafeR mode performance. Pacing Clin Electrophysiol. 2009;32 Suppl 1: S231-235.

256. Thibault B, Ducharme A, Baranchuk A, et al., CAN-SAVE R Study Investigators. Very low ventricular pacing rates can be achieved safely in a heterogeneous pacemaker population and provide clinical benefits: the CANadian Multi-Centre Randomised Study-Spontaneous AtrioVEntricular Conduction pReservation (CAN-SAVE R) Trial. J Am Heart Assoc. 2015;4:e001983.

257. Bellocci F, Spampinato A, Ricci R, et al. Antiarrhythmic benefits of dual chamber stimulation with rate-response in patients with paroxysmal atrial fibrillation and chronotropic incompetence: a prospective, multicentre study. Europace. 1999;1:220-5.

258. Santini M, Ricci R, Puglisi A, et al. Long-term haemodynamic and antiarrhythmic benefits of DDIR versus DDI pacing mode in sick sinus syndrome and chronotropic incompetence. G Ital Cardiol. 1997;27:892-900.

259. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20:e1-e160.

260. Chen YW, Bai R, Lin T, et al. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related tachycardia_bradycardia syndrome? Pacing Clin Electrophysiol. 2014;37:403-11.

261. Fleischmann KE, Orav EJ, Lamas GA, et al. Pacemaker implantation and quality of life in the Mode Selection Trial (MOST). Heart Rhythm. 2006;3:653-9.

262. Capucci A, Boriani G, Specchia S, et al. Evaluation by cardiopulmonary exercise test of DDDR versus DDD pacing. Pacing Clin Electrophysiol. 1992;15:1908-13.

263. Lamas GA, Knight JD, Sweeney MO, et al. Impact of ratemodulated pacing on quality of life and exercise capacity — evidence from the Advanced Elements of Pacing Randomized Controlled Trial (ADEPT). Heart Rhythm. 2007;4:1125-32.

264. Hocini M, Sanders P, Deisenhofer I, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation. 2003;108:1172-5.

265. Raviele A, Proclemer A, Gasparini G, et al. Long-term follow-up of patients with unex-plained syncope and negative electrophysiologic study. Eur Heart J. 1989;10:127-32.

266. Inada K, Yamane T, Tokutake K, et al. The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up. Europace. 2014;16:208-13.

267. Jim MH, Chan AO, Tse HF, et al. Clinical and angiographic findings of complete atrioventricular block in acute inferior myocardial infarction. Ann Acad Med Singapore. 2010;39:185-90

268. Crossley GH, Padeletti L, Zweibel S, et al. Reactive atrial-based antitachycardia pacing therapy reduces atrial tachyarrhythmias. Pacing Clin Electrophysiol. 2019;42:970-9.

269. Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation. 2014;130:94-125.

270. Mueller TC, Loos M, Haller B, et al. Intra-operative wound irrigation to reduce surgical site infections after abdominal surgery: a systematic review and meta-analysis. Langenbeck’s Arch Surg. 2015;400:167-81.

271. Darouiche RO, Wall MJ Jr, Itani KM, et al. Chlorhexidinealcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med. 2010;362:18-26.

272. Mimoz O, Lucet J-C, Kerforne T, Pascal J, et al. Skin antisepsis with chlorhexidinealcohol versus povidone iodinealcohol, with and without skin scrubbing, for prevention of intravascular-catheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet. 2015;386:2069-77.

273. Bradshaw PJ, Stobie P, Knuiman MW, et al. Trends in the incdence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart. 2014;1:e000177.

274. Birnie DH, Sauer WH, Judson MA. Consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart. 2016;102:411-4.

275. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-23.

276. Mankad P, Mitchell B, Birnie D, Kron J. Cardiac sarcoidosis. Curr Cardiol Rep. 2019;21:152.

277. Laurenzi F, Achilli A, Avella A, et al. Mortality in myotonic dystrophy patients in the area of prophylactic pacing devices. Int J Cardiol. 2011;150:54-8.

278. Strasberg B, Amat YLF, Dhingra RC, et al. Natural history of chronic second-degree atrioventricular nodal block. Circulation. 1981;63:1043-9.

279. Bhakta D, Shen C, Kron J, et al. Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population. J Cardiovasc Electrophysiol. 2011;22:1369-75.

280. Facenda-Lorenzo M, Hernandez-Afonso J, Rodriguez-Esteban M, et al. Cardiac manifestations in myotonic dystrophy type 1 patients followed using a standard protocol in a specialized unit. Rev Esp Cardiol (Engl Ed). 2013;66:193-7.

281. Groh WJ. Arrhythmias in the muscular dystrophies. Heart Rhythm. 2012;9:1890-5.

282. Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688-97.

283. Ha AH, Tarnopolsky MA, Bergstra TG, et al. Predictors of atrio-ventricular conduction disease, long-term outcomes in patients with myotonic dystrophy types I and II. Pacing Clin Electrophysiol. 2012;35:1262-9.

284. Kabunga P, Lau AK, Phan K, et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol. 2015;181:303-10.

285. Lazarus A, Varin J, Babuty D, et al. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol. 2002;40:1645-52.

286. Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA. 2012;307:1292-301.

287. Hilgard J, Ezri MD, Denes P. Significance of ventricular pauses of three seconds or more detected on twenty-four-hour Holter recordings. Am J Cardiol. 1985;55:1005-8.

288. Saxon LA, Albert BH, Uretz EF, et al. Permanent pacemaker placement in chronic atrial fibrillation associated with intermittent AV block and cerebral symptoms. Pacing Clin Electrophysiol. 1990;13:724-9.

289. Shaw DB, Kekwick CA, Veale D, et al. Survival in second degree atrioventricular block. Br Heart J. 1985;53:587-93.

290. Simon AB, Zloto AE. Atrioventricular block: natural history after permanent ventricular pacing. Am J Cardiol. 1978;41:500-7.

291. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425.

292. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-426.

293. Second Chinese Cardiac Study (CCS-2) Collaborative Group. Rationale, design and organization of the Second Chinese Cardiac Study (CCS-2): a randomized trial of clopidogrel plus aspirin, and of metoprolol, among patients with suspected acute myocardial infarction. Second Chinese Cardiac Study (CCS-2) Collaborative Group. J Cardiovasc Risk. 2000;7(6):435-41.

294. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-8.

295. Dargie HJ. Design and methodology of the CAPRICORN trial — a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction. Eur J Heart Fail. 2000;2:325-32.

296. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-7.

297. Kiehl EL, Makki T, Kumar R, et al. Incidence and predictors of right ventricular pacingin-duced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13:2272-8.

298. Kato Y, Morimoto S, Uemura A, et al. Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis. 2003;20:133-7.

299. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046-51.

300. Sadek MM, Yung D, Birnie DH, et al. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29:1034-41.

301. Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J. 2015;36:1098-105.

302. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505-9.

303. Zhou Y, Lower EE, Li HP, et al. Cardiac sarcoidosis: the impact of age and implanted devices on survival. Chest. 2017;151:139-48.

304. Arbustini E, Pilotto A, Repetto A, et al. Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol. 2002;39:981-90.

305. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. HeartRhythm. 2013;10:1492-8.

306. Lawrenz T, Lieder F, Bartelsmeier M, et al. Predictors of complete heart block after trans-coronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2007;49:2356-63.

307. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42:296-300.

308. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733-79.

309. Arnold AD, Howard JP, Chiew K, et al. Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials. Eur Heart J Qual Care Clin Outcomes. 2019;5:321-33.

310. Lau CP, Rushby J, Leigh-Jones M, et al. Symptomatology and quality of life in patients with rate-responsive pacemakers: a double-blind, randomized, crossover study. Clin Cardiol. 1989;12:505-12.

311. Leung SK, Lau CP. Developments in sensor-driven pacing. Cardiol Clin. 2000;18:113-55, ix. 203.

312. Proietti R, Manzoni G, Di Biase L, et al. Closed loop stimulation is effective in improving heart rate and blood pressure response to mental stress: report of a single-chamber pacemaker study in patients with chronotropic incompetent atrial fibrillation. Pacing Clin Electrophysiol. 2012;35:990-8.

313. Shaw DB, Gowers JI, Kekwick CA, et al. Is Mobitz type I atrioventricular block benign in adults? Heart. 2004;90:169-74.

314. Coumbe AG, Naksuk N, Newell MC, et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart. 2013;99:334-8.

315. Barold SS. Indications for permanent cardiac pacing in first-degree AV block: class I, II, or III? Pacing Clin Electrophysiol. 1996;19:747-51.

316. Brecker SJ, Xiao HB, Sparrow J, Gibson DG. Effects of dual-chamber pacing with short atrioventricular delay in dilated cardiomyopathy. Lancet. 1992;340:1308-12.

317. Carroz P, Delay D, Girod G. Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block. Europace. 2010;12:594-6.

318. Scheinman MM, Peters RW, Suave MJ, et al. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing. Am J Cardiol. 1982;50:1316-22.

319. Morady F, Higgins J, Peters RW, et al. Electrophysiologic testing in bundle branch block and unexplained syncope. Am J Cardiol. 1984;54:587-91.

320. Kubis M, Svejda J. Indication of permanent pacing after acute myocardial infarction complicated by combined intraventricular block. Cor Vasa. 1982;24:295-301.

321. Witt CM, Wu G, Yang D, et al. Outcomes with left bundle branch block and mildly to moderately reduced left ventricular function. JACC Heart Fail. 2016;4:897-903.

322. Chung ES, Katra RP, Ghio S, et al. Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. Eur J Heart Fail. 2010;12:581-7.

323. Peters RW, Scheinman MM, Modin C, et al. Prophylactic permanent pacemakers for patients with chronic bundle branch block. Am J Med. 1979;66:978-85.

324. DePasquale NP, Bruno MS. Natural history of combined right bundle branch block and left anterior hemiblock (bilateral bundle branch block). Am J Med. 1973;54:297-303.

325. Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69-77.

326. Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. 2012;35:131-4.

327. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503-51.

328. Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder management procedures. Circulation. 2018;137:24-33.

329. Santini M, Castro A, Giada F, et al. Prevention of syncope through permanent cardiac pacing in patients with bifascicular blockand syncope of unexplained origin: the PRESS study. Circ Arrhythm Electrophysiol. 2013;6:101-7.

330. Olshansky B, Day JD, Sullivan RM, et al. Does cardiac resynchronization therapy provide unrecognized benefit in patients with prolonged PR intervals? The impact of restoring atrioventricular synchrony: an analysis from the COMPANION Trial. Heart Rhythm. 2012;9:34-9.

331. Gervais R, Leclercq C, Shankar A, et al., CARE-HF investigators. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial. Eur J Heart Fail. 2009;11:699-705.

332. Friedman DJ, Bao H, Spatz ES, et al. Association Between a Prolonged PR interval and outcomes of cardiac resynchronization therapy: a report from the National Cardiovascular Data Registry. Circulation. 2016;134:1617-28.

333. Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol. 2002;39:194-201.

334. Leclercq C, Hare JM. Ventricular resynchronization: current state of the art. Circulation. 2004;109:296-9.

335. Cunnington C, Kwok CS, Satchithananda DK, et al. Cardiac resynchronisation therapy is not associated with a reduction in mortality or heart failure hospitalisation in patients with non-left bundle branch block QRS morphology: meta-analysis of randomized controlled trials. Heart. 2015;101:1456-62.

336. Zareba W, Klein H, Cygankiewicz I, et al. Effectiveness of cardiac resynchronization therapy by QRS morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;123:1061-72.

337. Birnie DH, Ha A, Higginson L, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail. 2013;6:1190-8.

338. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010;122:2022-30.

339. Woods B, Hawkins N, Mealing S, et al. Individual patient data network metaanalysis of mortality effects of implantable cardiac devices. Heart. 2015;101:1800-6.

340. Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012;126:822-9.

341. Fantoni C, Kawabata M, Massaro R, et al. Right and left ventricular activation sequence in patients with heart failure and right bundle branch block: a detailed analysis using three-dimensional non-fluoroscopic electroanatomic mapping system. J Cardiovasc Electrophysiol. 2005;16:112-9; discussion 120-121.

342. Nery PB, Ha AC, Keren A, Birnie DH. Cardiac resynchronization therapy in patients with left ventricular systolic dysfunction and right bundle branch block: a systematic review. Heart Rhythm. 2011;8:1083-7.

343. Kutyifa V, Stockburger M, Daubert JP, et al. PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. Circ Arrhythm Electrophysiol. 2014;7:645-51.

344. Kewcharoen J, Kanitsoraphan C. Prolonged PR interval and outcome in cardiac resynchronization therapy. Arq Bras Cardiol. 2019;113:109-10.

345. Caputo ML, van Stipdonk A, Illner A, et al. The definition of left bundle branch block influences the response to cardiac resynchronization therapy. Int J Cardiol. 2018;269:165-9.

346. Van Stipdonk AMW, Vanbelle S, Ter Horst IAH, et al. Large variability in clinical judgement and definitions of left bundle branch block to identify candidates for cardiac resynchronisation therapy. Int J Cardiol. 2019;286:61-5.

347. Tomlinson DR, Bashir Y, Betts TR, Rajappan K. Accuracy of manual QRS duration assessment: its importance in patient selection for cardiac resynchronization and implantable cardioverter defibrillator therapy. Europace. 2009;11:638-42.

348. Vancura V, Wichterle D, Ulc I, et al. The variability of automated QRS duration measurement. Europace. 2017;19:636-43.

349. Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med. 2010;363:2385-95.

350. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.

351. Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361:1329-38.

352. Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol. 2002;39:2026-33.

353. Auricchio A, Stellbrink C, Butter C, et al. Clinical efficacy of cardiac resynchronization therapy using left ventricular pacing in heart failure patients stratified by severity of ventricular conduction delay. J Am Coll Cardiol. 2003;42:2109-16.

354. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873-80.

355. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol. 2002;40:111-8.

356. Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure. N Engl J Med. 2002;346:1845-53.

357. Abraham WT, Young JB, Leon AR, et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation. 2004;110:2864-8.

358. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advancedchronic heart failure. N Engl J Med. 2004;350:2140-50.

359. Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J. 2006;27:1928-32.

360. Linde C, Abraham WT, Gold MR, et al. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008;52:1834-43.

361. Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54:1837-46.

362. Ruschitzka F, Abraham WT, Singh JP, et al. Cardiacresynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395-405.

363. Goldenberg I, Kutyifa V, Moss AJ. Survival with cardiac-resynchronization therapy. N Engl J Med. 2014;371:477-8.

364. Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547-56.

365. Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med. 2014;174:1340-8.

366. Zweerink A, Friedman DJ, Klem I, et al. Size Matters: Normalization of QRS duration to left ventricular dimension improves prediction of long-term cardiac resynchronization therapy outcome. Circ Arrhythm Electrophysiol. 2018;11:e006767.

367. Krongrad E. Prognosis for patients with congenital heart disease and postoperative intraventricular conduction defects. Circulation. 1978;57:867-70.

368. Holt ND, McComb JM. Cardiac transplantation and pacemakers: when and what to implant. Card Electrophysiol Rev. 2002;6:140-51.

369. Auffret V, Webb JG, Eltchaninoff H, et al. Clinical impact of baseline right bundle branch block in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2017;10:1564-74.

370. Junquera L, Freitas-Ferraz AB, Padron R, et al. Intraprocedural high-degree atrioventricular block or complete heart block in transcatheter aortic valve replacement recipients with no prior intraventricular conduction disturbances. Catheter Cardiovasc Interv. 2019;95:982-90.

371. Jorgensen TH, De Backer O, Gerds TA, et al. Immediate post-procedural 12-lead electrocardiography as predictor of late conduction defects after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:1509-18.

372. Rodes-Cabau J, Urena M, Nombela-Franco L, et al. Arrhythmic burden as determined by ambulatory continuous cardiac monitoring in patients with new-onset persistent left bundle branch block following transcatheter aortic valve replacement: the MARE study. JACC Cardiovasc Interv. 2018;11:1495-505.

373. Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. Eur Heart J. 2015;36:1983-9.

374. Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol. 2011;57:813-20.

375. Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: the CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail. 2013;1:500-7.

376. Yin J, Hu H, Wang Y, et al. Effects of atrioventricular nodal ablation on permanent atrial fibrillation patients with cardiac resynchronization therapy: a systematic review and meta-analysis. Clin Cardiol. 2014;37:707-15.

377. Tolosana JM, Arnau AM, Madrid AH, et al. Cardiac resynchronization therapy in patients with permanent atrial fibrillation. Is it mandatory to ablate the atrioventricular junction to obtain a good response? Eur J Heart Fail. 2012;14:635-41.

378. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962.

379. Zhang XH, Chen H, Siu CW, et al. New-onset heart failure after permanent right ventricular apical pacing in patients with acquired high-grade atrioventricular block and normal left ventricular function. J Cardiovasc Electrophysiol. 2008;19:136-41.

380. Tolosana JM, Trucco E, Khatib M, et al. Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy. Eur J Heart Fail. 2013;15:1412-8.

381. Doshi RN, Daoud EG, Fellows C, et al., PAVE Study Group. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005;16:1160-5.

382. Huang W, Su L, Wu S, et al. Benefits of permanent His bundle pacing combined with atrioventricular node ablation in atrial fibrillation patients with heart failure with both preserved and reduced left ventricular ejection fraction. J Am Heart Assoc. 2017;6:e005309.

383. Yu CM, Chan JY, Zhang Q, et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med. 2009;361:2123-34.

384. McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. doi:10.1093/eurheartj/ehab368. Erratum in: Eur Heart J. 2021;42(48):4901. doi:10.1093/eurheartj/ehab670.

385. Fujita B, Schmidt T, Bleiziffer S, et al., GARY Executive Board. Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. Eur J Cardiothorac Surg. 2020;57:151-9.

386. Wilkoff BL, Cook JR, Epstein AE, et al. Dual Chamber VVI Implantable Defibrillator Trial Investigators. Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial. JAMA. 2002;288:3115-23.

387. Curtis AB, Worley SJ, Adamson PB, et al. Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block Trial Investigators. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med. 2013;368:1585-93.

388. Baker CM, Christopher TJ, Smith PF, et al. Addition of a left ventricular lead to conventional pacing systems in patients with congestive heart failure: feasibility, safety, and early results in 60 consecutive patients. Pacing Clin Electrophysiol. 2002;25:1166-71.

389. Valls-Bertault V, Fatemi M, Gilard M, et al. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation. Europace. 2004;6:438-43.

390. Eldadah ZA, Rosen B, Hay I, et al. The benefit of upgrading chronically right ventricle-paced heart failure patients to resynchronization therapy demonstrated by strain rate imaging. Heart Rhythm. 2006;3:435-42.

391. Shimano M, Tsuji Y, Yoshida Y, et al. Acute and chronic effects of cardiac resynchronization in patients developing heart failure with long-term pacemaker therapy for acquired complete atrioventricular block. Europace. 2007;9:869-74.

392. Laurenzi F, Achilli A, Avella A, et al. Biventricular upgrading in patients with conventional pacing system and congestive heart failure: results and response predictors. Pacing Clin Electrophysiol. 2007;30:1096-104.

393. Vatankulu MA, Goktekin O, Kaya MG, et al. Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009;103:1280-4.

394. Hoijer CJ, Meurling C, Brandt J. Upgrade to biventricular pacing in patients withconventional pacemakers and heart failure: a double-blind, randomized crossoverstudy. Europace. 2006;8:51-5.

395. Delnoy PP, Ottervanger JP, Vos DH, et al. Upgrading to biventricular pacing guided by pressure _volume loop analysis during implantation. J Cardiovasc Electrophysiol. 2011;22:677-83.

396. Van Geldorp IE, Vernooy K, Delhaas T, et al. Beneficial effects of biventricular pacing in chronically right ventricular paced patients with mild cardiomyopathy. Europace. 2010;12:223-9.

397. Leclercq C, Cazeau S, Lellouche D, et al. Upgrading from single chamber right ventricular to biventricular pacing in permanently paced patients with worsening heart failure: the RD-CHF Study. Pacing Clin Electrophysiol. 2007;30 Suppl 1: S23_S30.

398. Kosztin A, Vamos M, Aradi D, et al. De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis. Heart Fail Rev. 2018;23:15-26.

399. Linde CM, Normand C, Bogale N, et al. Upgrades from a previous device compared to de novo cardiac resynchronization therapy in the European Society of Cardiology CRT Survey II. II. Eur J Heart Fail. 2018;20:1457-68.

400. Urena M, Webb JG, Tamburino C, et al. Permanent pacemaker implantation after transcatheter aortic valve implantation: impact on late clinical outcomes and left ventricular function. Circulation. 2014;129:1233-43.

401. Funck RC, Mueller HH, Lunati M, et al. Characteristics of a large sample of candidates for permanent ventricular pacing included in the Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization Study (BioPace). Europace. 2014;16:354-62.

402. Yu CM, Fang F, Luo XX, et al. Long-term follow-up results of the pacing to avoid cardiac enlargement (PACE) trial. Eur J Heart Fail. 2014;16:1016-25.

403. Albertsen AE, Mortensen PT, Jensen HK, et al. Adverse effect of right ventricular pacing prevented by biventricular pacing during long-term follow-up: a randomized comparison. Eur J Echocardiogr. 2011;12:767-72.

404. Ueshima D, Nai Fovino L, Mojoli M, et al. The interplay between permanent pacemaker implantation and mortality in patients treated by transcatheter aortic valve implantation: a systematic review and meta-analysis. Catheter Cardiovasc Interv. 2018;92:E159E167.

405. Keene D, Arnold AD, Jastrzebski M, et al. His bundle pacing, learning curve, procedure characteristics, safety, and feasibility: insights from a large international observational study. J Cardiovasc Electrophysiol. 2019;30:1984-93.

406. Teigeler T, Kolominsky J, Vo C, et al. Intermediate term performance and safety of His bundle pacing leads: a single center experience. Heart Rhythm. 2021;18:743-9.

407. Zweerink A, Bakelants E, Stettler C, Burri H. Cryoablation vs. radiofrequency ablation of the atrioventricular node in patients with His-bundle pacing. Europace. 2021;23(3):421-30. doi:10.1093/europace/euaa344.

408. Starr N, Dayal N, Domenichini G, et al. Electrical parameters with His-bundle pacing: considerations for automated programming. Heart Rhythm. 2019;16:1817-24.

409. Burri H, Keene D, Whinnett Z, et al. Device programming for His bundle pacing. Circ Arrhythm Electrophysiol. 2019;12:e006816.

410. Vijayaraman P, Naperkowski A, Ellenbogen KA, Dandamudi G. Electrophysiologic insights into site of atrioventricular block. JACC Clin Electrophysiol. 2015;1:571-81.

411. Abdelrahman M, Subzposh FA, Beer D, et al. Clinical outcomes of His bundle pacing compared to right ventricular pacing. J Am Coll Cardiol. 2018;71:2319-30.

412. Sharma PS, Dandamudi G, Herweg B, et al. Permanent His-bundle pacing as an alternative to biventricular pacing for cardiac resynchronization therapy: a multicenter experience. Heart Rhythm. 2018;15:413-20.

413. Vijayaraman P, Dandamudi G, Zanon F, et al. Permanent His bundle pacing: recommendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up. Heart Rhythm. 2018;15:460-8.

414. Giraldi F, Cattadori G, Roberto M, et al. Long-term effectiveness of cardiac resynchronization therapy in heart failure patients with unfavorable cardiac veins anatomy comparison of surgical versus hemodynamic procedure. J Am Coll Cardiol. 2011;58:483-90.

415. Barba-Pichardo R, Manovel Sanchez A, et al. Ventricular resynchronization therapy by direct His-bundle pacing using an internal cardioverter defibrillator. Europace. 2013;15:83-8.

416. Mohananey D, Jobanputra Y, Kumar A, et al. Clinical and echocardiographic outcomes following permanent pacemaker implantation after transcatheter aortic valve replacement: metaanalysis and meta-regression. Circ Cardiovasc Interv. 2017;10:e005046.

417. Deshmukh P, Casavant DA, Romanyshyn M, Anderson K. Permanent, direct His-bundle pacing: a novel approach to cardiac pacing in patients with normal His_Purkinje activation. Circulation. 2000;101:869-77.

418. Occhetta E, Bortnik M, Magnani A, et al. Prevention of ventricular desynchronization by permanent para-Hisian pacing after atrioventricular node ablation in chronic atrial fibrillation: a crossover, blinded, randomized study versus apical right ventricular pacing. J Am Coll Cardiol. 2006;47:1938-45.

419. Chamandi C, Barbanti M, Munoz-Garcia A, et al. Long-term outcomes in patients with new permanent pacemaker implantation following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2018;11:301-10.

420. Bougioukas I, Jebran AF, Grossmann M, et al. Is there a correlation between late reexploration after cardiac surgery and removal of epicardial pacemaker wires? J Cardiothorac Surg. 2017;12:3.

421. Gordon RS, Ivanov J, Cohen G, et al. Permanent cardiac pacing after a cardiac operation: predicting the use of permanent pacemakers. AnnThoracSurg. 1998;66:1698-704.

422. Caspi Y, Safadi T, Ammar R, et al. The significance of bundle branch block in the immediate postoperative electrocardiograms of patients undergoing coronary artery bypass. J Thorac Cardiovasc Surg. 1987;93:442-6.

423. Cook DJ, Bailon JM, Douglas TT, et al. Changing incidence, type, and natural history of conduction defects after coronary artery bypass grafting. Ann Thorac Surg. 2005;80:1732-7.

424. Mackstaller LL, Alpert JS. Atrial fibrillation: a review of mechanism, etiology, and therapy. Clin Cardiol. 1997;20:640-50.

425. Ngaage DL, Schaff HV, Mullany CJ, et al. Does preoperative atrial fibrillation influence early and late outcomes of coronary artery bypass grafting? J Thorac Cardiovasc Surg. 2007;133:182-9.

426. Puskas JD, Sharoni E, Williams WH, et al. Is routine use of temporary epicardial pacing wires necessary after either OPCAB or conventional CABG/CPB? Heart Surg Forum. 2003;6:E103-6.

427. Satinsky JD, Collins JJ Jr, Dalen JE. Conduction defects after cardiac surgery. Circulation. 1974;50:Ii170-4.

428. Tuzcu EM, Emre A, Goormastic M, et al. Incidence and prognostic significance of intraventricular conduction abnormalities after coronary bypass surgery. J Am Coll Cardiol. 1990;16:607-10.

429. Yesil M, Bayata S, Arikan E, et al. Should we revascularize before implanting a pacemaker? Clin Cardiol. 2008;31:498-501.

430. Zeldis SM, Morganroth J, Horowitz LN, et al. Fascicular conduction disturbances after coronary bypass surgery. Am J Cardiol. 1978;41:860-4.

431. Bethea BT, Salazar JD, Grega MA, et al. Determining the utility of temporary pacing wires after coronary artery bypass surgery. Ann Thorac Surg. 2005;79:104-7.

432. Diemberger I, Mazzotti A, Giulia MB, et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. Expert Rev Med Devices. 2013;10:551-73.

433. Merchant FM, Tejada T, Patel A, et al. Procedural outcomes and long-term survival associated with lead extraction in patients with abandoned leads. Heart Rhythm. 2018;15:855-9.

434. Hauser RG, Hayes DL, Kallinen LM, et al. Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm. 2007;4:154-60.

435. Vuorinen AM, Pakarinen S, Jaakkola I, et al. Clinical experience of magnetic resonance imaging in patients with cardiac pacing devices: unrestricted patient population. Acta Radiol. 2019;60:1414-21.

436. Horwood L, Attili A, Luba F, et al. Magnetic resonance imaging in patients with cardiac implanted electronic devices: focus on contraindications to magnetic resonance imaging protocols. Europace. 2017;19:812-7.

437. Bagur R, Manazzoni JM, Dumont É, et al. Permanent pacemaker implantation following isolated aortic valve replacement in a large cohort of elderly patients with severe aortic stenosis. Heart. 2011;97:1687-94.

438. Dawkins S, Hobson AR, Kalra PR, et al. Permanent pacemaker implantation after isolated aortic valve replacement: incidence, indications, and predictors. Ann Thorac Surg. 2008;85:108-12.

439. Limongelli G, Ducceschi V, D’Andrea A, et al. Risk factors for pacemaker implantation following aortic valve replacement: a single centre experience. Heart. 2003;89:901-4.

440. Higgins JV, Gard JJ, Sheldon SH, et al. Safety and outcomes of magnetic resonance imaging in patients with abandoned pacemaker and defibrillator leads. Pacing Clin Electrophysiol. 2014;37:1284-90.

441. Gimbel JR, Bello D, Schmitt M, et al. Randomized trial of pacemaker and lead system for safe scanning at 1.5 Tesla. Heart Rhythm. 2013;10:685-91.

442. Shenthar J, Milasinovic G, Al Fagih A, et al. MRI scanning in patients with new and existing CapSureFix Novus 5076 pacemaker leads: randomized trial results. Heart Rhythm. 2015;12:759-65.

443. Baraki H, Al Ahmad A, Jeng-Singh S, et al. Pacemaker dependency after isolated aortic valve replacement: do conductance disorders recover over time? Interact Cardiovasc Thorac Surg. 2013;16:476-81.

444. Greason KL, Lahr BD, Stulak JM, et al. Long-Term Mortality Effect of Early Pacemaker Implantation After Surgical Aortic Valve Replacement. Ann Thorac Surg. 2017;104:1259-64.

445. Schurr UP, Berli J, Berdajs D, et al. Incidence and risk factors for pacemaker implantation following aortic valve replacement. Interact Cardiovasc Thorac Surg. 2010; 11:556-60.

446. Berdajs D, Schurr UP, Wagner A, et al. Incidence and pathophysiology of atrioventricular block following mitral valve replacement and ring annuloplasty. Eur J Cardiothorac Surg. 2008;34:55-61.

447. Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med. 2016;374:344-53.

448. Levin R, Leacche M, Petracek MR, et al. Extending the use of the pacing pulmonary artery catheter for safe minimally invasive cardiac surgery. J Cardiothor Vasc Anesthes. 2010;24:568-73.

449. Nazarian S, Hansford R, Rahsepar AA, et al. Safety of magnetic resonance imaging in patients with cardiac devices. N Engl J Med. 2017;377:2555-64.

450. Chikwe J, Itagaki S, Anyanwu A, et al. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol. 2015;65:1931-8.

451. Jokinen JJ, Turpeinen AK, Pitkanen O, et al. Pacemaker therapy after tricuspid valve operations: implications on mortality, morbidity, and quality of life. Ann Thorac Surg. 2009;87:1806-14.

452. McCarthy PM, Bhudia SK, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg. 2004;127:674-85.

453. Scully HE, Armstrong CS. Tricuspid valve replacement. Fifteen years of experience with mechanical prostheses and bioprostheses. J Thorac Cardiovasc Surg. 1995;109:1035-41.

454. Chung MK. Cardiac surgery: postoperative arrhythmias. Crit Care Med. 2000;28:N136N14.

455. Knops RE, Tjong FV, Neuzil P, et al. Chronic performance of a leadless cardiac pacemaker: 1-year follow-up of the LEADLESS trial. J Am Coll Cardiol. 2015;65:1497-504.

456. Hill TE, Kiehl EL, Shrestha NK, et al. Predictors of permanent pacemaker requirement after cardiac surgery for infective endocarditis. Eur Heart J Acute Cardiovasc Care. 2021;10:329-34.

457. Gammie JS, Haddad M, Milford-Beland S, et al. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons National Cardiac Database. Ann Thorac Surg. 2008;85:909-14.

458. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015;372:1399-409.

459. Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart. 2014;100:722-30.

460. Saint LL, Damiano RJ Jr, Cuculich PS, et al. Incremental risk of the Cox-maze IV procedure for patients with atrial fibrillation undergoing mitral valve surgery. J Thorac Cardiovasc Surg. 2013;146:1072-7.

461. Lee R, McCarthy PM, Wang EC, et al. Midterm survival in patients treated for atrial fibrillation: a propensity-matched comparison to patients without a history of atrial fibrillation. J Thorac Cardiovasc Surg. 2012;143:1341-51; discussion 50-1.

462. Ad N, Suri RM, Gammie JS, et al. Surgical ablation of atrial fibrillation trends and outcomes in North America. J Thorac Cardiovasc Surg. 2012;144:1051-60.

463. De Cock CC, Vinkers M, Van Campe LC, et al. Long-term outcome of patients with multiple (> or = 3) noninfected transvenous leads: a clinical and echocardiographic study. Pacing Clin Electrophysiol. 2000;23:423-6.

464. Noheria A, van Zyl M, Scott LR, et al. Single-site ventricular pacing via the coronary sinus in patients with tricuspid valve disease. Europace. 2018;20:636-42.

465. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-607.

466. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364:2187-98.

467. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374:1609-20.

468. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med. 2019;380:1695-705.

469. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valvereplacement with a self-expanding prosthesis. N Engl J Med. 2014;370:1790-8.

470. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019;380:1706-15.

471. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376:1321-31.

472. Barbash IM, Finkelstein A, Barsheshet A, et al. Outcomes of patients at estimated low, intermediate, and high risk undergoing transcatheter aortic valve implantation for aortic stenosis. Am J Cardiol. 2015;116:1916-22.

473. Bekeredjian R, Szabo G, Balaban U, et al. Patients at low surgical risk as defined by the Society of Thoracic Surgeons Score undergoing isolated interventional or surgical aortic valve implantation: in-hospital data and 1-year results from the German Aortic Valve Registry (GARY). Eur Heart J. 2019;40:1323-30.

474. Gilard M, Eltchaninoff H, Iung B, et al. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366:1705-15.

475. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the U.K. TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011;58:2130-8.

476. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2010;122:62-9.

477. Werner N, Zahn R, Beckmann A, et al. Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve implantation for severe symptomatic aortic valve stenosis. Circulation. 2018;138:2611-23.

478. Fadahunsi OO, Olowoyeye A, Ukaigwe A, et al. Incidence, predictors, and outcomes of permanent pacemaker implantation following transcatheter aortic valve replacement: analysis from theU.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. JACC Cardiovasc Interv. 2016;9:2189-99.

479. Dizon JM, Nazif TM, Hess PL, et al. Chronic pacing and adverse outcomes after transcatheter aortic valve implantation. Heart. 2015;101:1665-71.

480. Glikson М, Nielsen J C, Kronborg M B, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA). Rev Esp Cardiol (Engl Ed). 2022;75(5):430. English, Spanish. doi:10.1016/j.rec.2022.04.004.

481. Piazza N, Onuma Y, Jesserun E, et al. Early and persistent intraventricular conduction abnormalities and requirements for pacemaking after percutaneous replacement of the aortic valve. JACC Cardiovasc Interv. 2008;1:310-6.

482. Siontis GC, Juni P, Pilgrim T, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64:129-40.

483. Boerlage-Van Dijk K, Kooiman KM, Yong ZY, et al. Predictors and permanency of cardiac conduction disorders and necessity of pacing after transcatheter aortic valve implantation. Pacing Clin Electrophysiol. 2014;37:1520-9.

484. Regueiro A, Abdul-Jawad Altisent O, Del Trigo M, et al. Impact of new-onset left bundle branch block and periprocedural permanent pacemaker implantation on clinical outcomes in patients undergoing transcatheter aortic valve replacement: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2016;9:e003635.

485. Watanabe Y, Kozuma K, Hioki H, et al. Pre-existing right bundle branch block increases risk for death after transcatheter aortic valve replacement with a balloon-expandable valve. JACC Cardiovasc Interv. 2016;9:2210-6.

486. Egger F, Nurnberg M, Rohla M, et al. High-degree atrioventricular block in patients with preexisting bundle branch block or bundle branch block occurring during transcatheter aortic valve implantation. Heart Rhythm. 2014;11:2176-82.

487. Roten L, Wenaweser P, Delacretaz E, et al. Incidence and predictors of atrioventricular conduction impairment after transcatheter aortic valve implantation. Am J Cardiol. 2010;106:1473-80.

488. Nazif TM, Dizon JM, Hahn RT, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRticTraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8:60-9.

489. Urena M, Mok M, Serra V, et al. Predictive factors and long-term clinical consequences of persistent left bundle branch block following transcatheter aortic valve implantation with a balloon-expandable valve. J Am Coll Cardiol. 2012;60:1743-52.

490. Testa L, Latib A, De Marco F, et al. Clinical impact of persistent left bundle-branch block after transcatheter aortic valve implantation with CoreValveRevalving System. Circulation. 2013;127:1300-7.

491. Franzoni I, Latib A, Maisano F, et al. Comparison of incidence and predictors of left bundle branch block after transcatheter aortic valve implantation using the CoreValve versus the Edwards valve. Am J Cardiol. 2013;112:554-9.

492. Toggweiler S, Stortecky S, Holy E, et al. The electrocardiogram after transcatheter aortic valve replacement determines the risk for post-procedural high-degree AV block and the need for telemetry monitoring. JACC Cardiovasc Interv. 2016;9:1269-76.

493. Van der Boon RM, Van Mieghem NM, Theuns DA, et al. Pacemaker dependency after transcatheter aortic valve implantation with the self-expanding Medtronic Core Valve System. Int J Cardiol. 2013;168:1269-73.

494. Mauri V, Reimann A, Stern D, et al. Predictors of permanent pacemaker implantation after transcatheter aortic valve replacement with the SAPIEN 3. JACC Cardiovasc Interv. 2016;9:2200-9.

495. Schymik G, Tzamalis P, Bramlage P, et al. Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort. Clin Res Cardiol. 2015;104:351-62.

496. Urena M, Webb JG, Eltchaninoff H, et al. Late cardiac death in patients undergoing transcatheter aortic valve replacement: incidence and predictors of advanced heart failure and sudden cardiac death. J Am Coll Cardiol. 2015;65:437-48.

497. Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation. 2006;113:2391-7.

498. Albin G, Hayes DL, Holmes DR Jr. Sinus node dysfunction in pediatric and young adult patients: treatment by implantation of a permanent pacemaker in 39 cases. Mayo Clin Proc. 1985;60:667-72.

499. Diller GP, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in adults with congenital heart disease. J Am Coll Cardiol. 2006;48:1250-6.

500. Fishberger SB, Wernovsky G, Gentles TL, et al. Factors that influence the development of atrial flutter after the Fontan operation. J Thorac Cardiovasc Surg. 1997;113:80-6.

501. Gelatt M, Hamilton RM, McCrindle BW, et al. Arrhythmia and mortality after the Mustard procedure: a 30-year single-center experience. J Am Coll Cardiol. 1997;29:194-201.

502. Helbing WA, Hansen B, Ottenkamp J, et al. Long-term results of atrial correction for transposition of the great arteries. Comparison of Mustard and Senning operations. J Thorac Cardiovasc Surg. 1994;108:363-72.

503. Sanders P, Morton JB, Kistler PM, et al. Electrophysiological and electroanatomic characterization of the atria in sinus node disease: evidence of diffuse atrial remodeling. Circulation. 2004;109:1514-22.

504. Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in the adult: functional status and complications. J Am Coll Cardiol. 1996;27:1238-43.

505. Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255-61.

506. Lundstrom U, Bull C, Wyse RK, et al. The natural and "unnatural" history of congenitally corrected transposition. Am J Cardiol. 1990;65:1222-9.

507. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med. 1987;316:835-9.

508. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation. 1995;92:442-9.

509. Glikson M, Dearani JA, Hyberger LK, et al. Indications, effectiveness, and long-term dependency in permanent pacing after cardiac surgery. Am J Cardiol. 1997;80:1309-13.

510. Kim MH, Deeb GM, Eagle KA, et al. Complete atrioventricular block after valvular heart surgery and the timing of pacemaker implantation. Am J Cardiol. 2001;87:649-51.

511. Rhodes LA, Walsh EP, Gamble WJ, et al. Benefits and potential risks of atrial antitachycardia pacing after repair of congenital heart disease. Pacing Clin Electrophysiol. 1995;18:1005-S8.2-16.

512. Stephenson EA, Casavant D, Tuzi J, et al. Efficacy of atrial antitachycardia pacing using the Medtronic AT500 pacemaker in patients with congenital heart disease. Am J Cardiol. 2003;92:871-6.

513. Janousek J, Paul T, Luhmer I, et al. Atrial baffle procedures for complete transposition of the great arteries: natural course of sinus node dysfunction and risk factors for dysrhythmias and sudden death. Z Kardiol. 1994;83:933-8.

514. DeSimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation. 2013;128:1433-41.

515. Auffret V, Loirat A, Leurent G, et al. High-degree atrioventricular block complicating ST segment elevation myocardial infarction in the contemporary era. Heart. 2016;102:40-9.

516. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation. Europace 2009;11:5461.

517. Mabo P, Victor F, Bazin P, et al. A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial). Eur Heart J. 2012;33:1105-11.

518. Kim HL, Kim SH, Seo JB, et al. Influence of second- and third-degree heart block on 30-day outcome following acute myocardial infarction in the drug-eluting stent era. Am J Cardiol. 2014;114:1658-62.

519. Ginks WR, Sutton R, Oh W, et al. Long-term prognosis after acute anterior infarction with atrioventricular block. Br Heart J. 1977;39:186-9.

520. Singh SM, FitzGerald G, Yan AT, et al. High-grade atrioventricular block in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events. Eur Heart J. 2015;36:976-83.

521. Watson RD, Glover DR, Page AJ, et al. The Birmingham trial of permanent pacing inpatients with intraventricular conduction disorders after acute myocardial infarction. Am Heart J. 1984;108:496-501.

522. Ritter WS, Atkins JM, Blomqvist CG, et al. Permanent pacing in patients with transient trifascicular block during acute myocardial infarction. Am J Cardiol. 1976;38:205-8.

523. Garcia-Fernandez FJ, Osca Asensi J, Romero R, et al. Safety and efficiency of a common and simplified protocol for pacemaker and defibrillator surveillance based on remote monitoring only: a long-term randomized trial (RM-ALONE). Eur Heart J 2019;40:1837-46.

524. Scheinman MM, Thorburn D, Abbott JA. Use of atropine in patients with acute myocardial infarction and sinus bradycardia. Circulation. 1975;52:627-33.

525. Swart G, Brady WJ Jr, DeBehnke DJ, et al. Acute myocardial infarction complicated by hemodynamically unstable bradyarrhythmia: prehospital and ED treatment with atropine. Am J Emerg Med. 1999;17:647-52.

526. Gang UJ, Hvelplund A, Pedersen S, et al. High-degree atrioventricular block complicating ST-segment elevation myocardial infarction in the era of primary percutaneous coronary intervention. Europace. 2012;14:1639-45.

527. Ghanbari H, Phard WS, Al-Ameri H, et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 2012;110:1482-88.

528. Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm 2005;2:907-11.

529. Cano O, Andres A, Alonso P, et al. Incidence and predictors of clinically relevant cardiac perforation associated with systematic implantation of active-fixation pacing and defibrillation leads: a single-centre experience with over 3800 implanted leads. Europace 2017;19:96-102.

530. Col JJ, Weinberg SL. The incidence and mortality of intraventricular conduction defects in acute myocardial infarction. Am J Cardiol. 1972;29:344-50.

531. Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion. Circulation. 1978;58:689-99.

532. Hindman MC, Wagner GS, JaRo M, et al. The clinical significance of bundle branch block complicating acute myocardial infarction. 1. Clinical characteristics, hospital mortality, and one-year follow-up. Circulation. 1978;58:679-88.

533. Alnsasra H, Ben-Avraham B, Gottlieb S, et al. High-grade atrioventricular block in patients with acute myocardial infarction. Insights from a contemporary multi-center survey. J Electrocardiol. 2018;51:386-91.

534. Kosmidou I, Redfors B, Dordi R, et al. Incidence, predictors, and outcomes of high-grade atrioventricular block in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol. 2017;119:1295-301.

535. Melgarejo-Moreno A, Galcera-Tomas J, Consuegra-Sanchez L, et al. Relation of new permanent right or left bundle branch block on short- and long-term mortality in acute myocardial infarction bundle branch block and myocardial infarction. Am J Cardiol. 2015;116:1003-9.

536. Brignole M, Menozzi C, Moya A, et al. International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation. 2012;125:2566-71.

537. Sud S, Klein GJ, Skanes AC, et al. Implications of mechanism of bradycardia on response to pacing in patients with unexplained syncope. Europace. 2007;9:312-8.

538. Brignole M, Arabia F, Ammirati F, et al, Syncope Unit Project 2 (SUP 2) investigators. Standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncope: 3-year insights from the Syncope Unit Project 2 (SUP 2) study. Europace. 2016;18:1427-33.

539. Puggioni E, Guiducci V, Brignole M, et al. Results and complications of the carotid sinus massage performed according to the "method of symptoms". Am J Cardiol. 2002;89:599-601.

540. Tarakji KG, Mittal S, Kennergren C, et al., WRAP-IT Investigators. Antibacterial envelope to prevent cardiac implantable device infection. N Engl J Med. 2019;380:18951905.

541. Brignole M, Menozzi C. The natural history of carotid sinus syncope and the effect of cardiac pacing. Europace. 2011;13:462-4.

542. Sutton R, Brignole M, Menozzi C, et al. Dualchamber pacing in the treatment of neurally mediated tilt-positive cardioinhibitory syncope: pacemaker versus no therapy: a multicenter randomized study. The Vasovagal Syncope International Study (VASIS) Investigators. Circulation. 2000;102:294-9.

543. Ammirati F, Colivicchi F, Santini M, Syncope Diagnosis and Treatment Study Investigators. Permanent cardiac pacing versus medical treatment for the prevention of recurrent vasovagal syncope: a multicenter, randomized, controlled trial. Circulation. 2001;104:52-7.

544. Baron-Esquivias G, Morillo CA, Moya-Mitjans A, et al. Dual-chamber pacing with closed loop stimulation in recurrent reflex vasovagal syncope: the SPAIN Study. J Am Coll Cardiol. 2017;70:1720-8.

545. Brignole M, Deharo JC, De Roy L, et al. Syncope due to idiopathic paroxysmal atrioventricular block: longterm follow-up of a distinct form of atrioventricular block. J Am Coll Cardiol. 2011;58:167-73.

546. Flammang D, Church TR, De Roy L, et al., ATP Multicenter Study. Treatment of unexplained syncope: a multicenter, randomized trial of cardiac pacing guided by adenosine 5’-triphosphate testing. Circulation. 2012;125:31-6.

547. Brignole M, Guieu R, Tomaino M, et al. Mechanism of syncope without prodromes with normal heart and normal electrocardiogram. Heart Rhythm. 2017;14:234-9.

548. Connolly SJ, Sheldon R, Thorpe KE, et al., VPS II Investigators. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224-9.

549. Raviele A, Giada F, Menozzi C, et al. A randomized, double-blind, placebo-controlled study of permanent cardiac pacing for the treatment of recurrent tilt-induced vasovagal syncope. The Vasovagal Syncope and Pacing Trial (SYNPACE). Eur Heart J. 2004;25:1741-8.

550. Brignole M, Deharo JC, Menozzi C, et al. The benefit of pacemaker therapy in patients with neurally mediated syncope and documented asystole: a meta-analysis of implantable loop recorder studies. Europace. 2018;20(8):1362-6. doi:10.1093/europace/eux321.

551. Proclemer A, Facchin D, Feruglio GA. [Syncope of unknown origin after electrophysiologic study: is the treatment with pacemaker useful?]. G Ital Cardiol. 1990;20:195-201.

552. Slade AK, Sadoul N, Shapiro L, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75:4449.

553. Behar JM, Bostock J, Zhu Li AP, et al. Cardiac resynchronization therapy delivered via a multipolar left ventricular lead is associated with reduced mortality and elimination of phrenic nerve stimulation: long-term follow-up from a multicenter registry. J Cardiovasc Electrophysiol. 2015;26:540-6.

554. Forleo GB, Di Biase L, Panattoni G, et al. Improved implant and postoperative lead performance in CRT-D patients implanted with a quadripolar left ventricular lead. A 6-month follow-up analysis from a multicenter rospective comparative study. J Interv Card Electrophysiol. 2015;42:5966.

555. Leyva F, Zegard A, Qiu T, et al. Cardiac resynchronization therapy using quadripolar versus non-quadripolar left ventricular leads programmed to biventricular pacing with single-site left ventricular pacing: impact on survival and heart failure hospitalization. J Am Heart Assoc 2017;6:e007026.

556. Hayes DL, Barold SS, Camm AJ, Goldschlager NF. Evolving indications for permanent cardiac pacing: an appraisal of the 1998 American College of Cardiology/American Heart Association Guidelines. Am J Cardiol. 1998;82:1082-6.

557. Epstein A, DiMarco J, Ellenbogen K, et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2008;117:2820-40.

558. Slotwiner D, Varma N, Akar JG, et al. Совместное экспертное заключение Американского общества сердечного ритма (HRS) по удаленной телеметрии и мониторингу сердечно-сосудистых имплантируемых электронных устройств. Вестник аритмологии. 2015;(82):43-72.

559. Sohail MR, Uslan DZ, Khan AH, et al. Anagement and outcome of permanentpacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49:1851-9.

560. Baddour LM, IDSA’s Emerging Infections Network. Long-term suppressiveantimicrobial therapy for intravascular device-related infections. Am J Med Sci. 2001;322:209-12.

561. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patientswith permanent pacemakers or implantable cardioverter-defibrillators. Circulation. 2001;104:1029-33.

562. Dy Chua J, Abdul-Karim A, Mawhorter S, et al. The role of swab and tissue culture in the diagnosis of implantable cardiac device infection. Pacing Clin Electrophysiol. 2005;28:1276-81.

563. Klug D, Lacroix D, Savoye C, et al. Systemic infection related to endocarditis on pacemakerleads: clinical presentation and management. Circulation. 1997;95:2098-107.

564. Mansur AJ, Grinberg M, Costa R, et al. Dura mater valveendocarditis related to retained fragment of postoperative temporary epicardial pacemaker lead. Am Heart J. 1984;108:1049-52.

565. Wilkoff BL, Love CJ, Byrd CL, et al. Heart Rhythm Society; American Heart Association. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm. 2009;6:1085-104.

566. Rusanov A, Spotnitz HM. A 15-year experience with permanent pacemaker and defibrillator lead and patch extractions. Ann Thorac Surg. 2010;89:44-50.

567. Riaz T, Nienaber JJ, Baddour LM, et al. Cardiovascular implantable electronic device infections in left ventricular assist device recipients. Pacing Clin Electrophysiology. 2014;37:225-30.

568. Viola GM, Awan LL, Ostrosky-Zeichner L, et al. Infections of cardiac implantable electronic devices: a retrospective multicenter observational study. Medicine (Baltimore). 2012;91:123-30.

569. Epstein AE, Kay GN, Plumb VJ, et al., ACT Investigators. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009;6:1136-43.

570. Lakshmanadoss U, Nuanez B, Kutinsky I, et al. Incidence of pocket infection postcardiac device implantation using antibiotic versus saline solution for pocket irrigation. Pacing Clin Electrophysiol. 2016;39:978-84.

571. Kang J, Simpson CS, Campbell D, et al. Case Report: Cardiac rhythm device contact dermatitis. Ann Noninvasive Electrocardiol. 2013;18:79-83.

572. Citerne O, Gomes S, Scanu P, Milliez P. Painful eczema mimicking pocket infection in a patient with an ICD. Circulation. 2011;123:1241-2.

573. Bode K, Breithardt OA, Kreuzhuber M, et al. Patient discomfort following catheter ablation and rhythm device surgery. Europace. 2015;17:1129-35.

574. Celikyurt U, Agacdiken A, Bozyel S, et al. Assessment of shoulder pain and shoulder disability in patients with implantable cardioverter-defibrillator. J Interv Card Electrophysiol. 2013;36:91-4.

575. Larsen JM, Theuns DA, Thøgersen AM. Paradoxical thromboembolic stroke during extraction of a recalled St Jude Medical Riata defibrillator lead with conductor externalization. Europace. 2014;16:240.

576. Noheria A, Ponamgi SP, Desimone CV, et al. Pulmonary embolism in patients with transvenous cardiac implantable electronic device leads. Europace. 2016;18:246-52.

577. Fu HX, Huang XM, Zhong L, et al. Outcome and management of pacemaker-induced superior vena cava syndrome. Pacing Clin Electrophysiol. 2014;37:1470-6.

578. Riley RF, Petersen SE, Ferguson JD, Bashir Y. Managing superior vena cava syndrome as a complication of pacemaker implantation: a pooled analysis of clinical practice. Pacing Clin Electrophysiol. 2010;33:420-5.

579. Sohal M, Williams S, Akhtar M, et al. Laser lead extraction to facilitate cardiac implantable electronic device upgrade and revision in the presence of central venous obstruction. Europace. 2014;16:81-7.

580. Gula LJ, Ames A, Woodburn A, et al. Central venous occlusion is not an obstacle to device upgrade with the assistance of laser extraction. Pacing Clin Electrophysiol. 2005;28:661-6.

581. Glikson M, Suleiman M, Luria DM, et al. Do abandoned leads pose risk to implantable cardioverter-defibrillator patients? Heart Rhythm. 2009;6:65-8.

582. Indik JH, Gimbel JR, Abe H, et al. 2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm. 2017;14:e97-e153.

583. Mollerus M, Albin G, Lipinski M, Lucca J. Magnetic resonance imaging of pacemakers and implantable cardioverter-defibrillators without specific absorption rate restrictions. Europace. 2010;12:947-51.

584. Lee JC, Epstein LM, Huffer LL, et al. ICD lead proarrhythmia cured by lead extraction. Heart Rhythm. 2009;6:613-8.

585. Valentino V, Greenberg YJ, Saunders P, Yang F. An unusual interaction between an abandoned pacing lead and an ICD lead. Heart Rhythm. 2015;12:1400-1.

586. Landolina M, Gasparini M, Lunati M, et al. Long-term complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation. 2011;123:2526-35.

587. Worley SJ, Gohn DC, Pulliam RW, et al. Subclavian venoplasty by the implanting physicians in 373 patients over 11 years. Heart Rhythm. 2011;8:526-33.

588. Cohen JD, Costa HS, Russo RJ. Determining the risks of magnetic resonance imaging at 1.5 tesla for patients with pacemakers and implantable cardioverter defibrillators. Am J Cardiol. 2012;110:1631-6.

589. Russo RJ, Costa HS, Silva PD, et al. Assessing the risks associated with MRI in patients with a pacemaker or defibrillator. N Engl J Med. 2017;376:755-64.

590. Nazarian S, Roguin A, Zviman MM, et al. Clinical utility and safety of a protocol for non-cardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation. 2006;114:1277-84.

591. Ji SY, Gundewar S, Palma EC. Subclavian venoplasty may reduce implant times and implant failures in the era of increasing device upgrades. Pacing Clin Electrophysiol. 2012;35:444-8.

592. Worley SJ, Gohn DC, Pulliam RW. Excimer laser to open refractory subclavian occlusion in 12 consecutive patients. Heart Rhythm. 2010;7:634-8.

593. Wazni O, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the-LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol. 2010;55:579-86.

594. Huang XM, Fu H, Osborn MJ, et al. Extraction of superfluous device leads: A comparison with removal of infected leads. Heart Rhythm. 2015;12:1177-82.

595. Wilkoff BL, Bello D, Taborsky M, et al. Magnetic resonance imaging in patients with a pacemaker system designed for the magnetic resonance environment. Heart Rhythm. 2011;8:65-73.

596. Naehle CP, Meyer C, Thomas D, et al. Safety of brain 3-T MR imaging with transmit-receive head coil in patients with cardiac pacemakers: pilot prospective study with 51 examinations. Radiology. 2008;249:991-1001.

597. Polewczyk A, Kutarski A, Tomaszewski A, et al. Lead dependent tricuspid dysfunction: analysis of the mechanism and management in patients referred for transvenous lead extraction. Cardiol J. 2013;20:402-10.

598. Padmanabhan D, Kella DK, Mehta R, et al. Safety of magnetic resonance imaging in patients with legacy pacemakers and defibrillators and abandoned leads. Heart Rhythm. 2017;14 (Suppl.): S105.

599. Austin CO, Landolfo K, Parikh PP, et al. Retained cardiac implantable electronic device fragments are not associated with magnetic resonance imaging safety issues, morbidity, or mortality after orthotopic heart transplant. Am Heart J. 2017;190:46-53.

600. Lin G, Nishimura RA, Connolly HM, et al. Severe symptomatic tricuspid valve regurgitation due to permanent pacemaker or implantable cardioverter-defibrillator leads. J Am Coll Cardiol. 2005;45:1672-5.

601. Postaci N, Ekşi K, Bayata S, Yeşil M. Effect of the number of ventricular leads on right ventricular hemodynamics in patients with permanent pacemaker. Angiology. 1995;46:421-4.

602. Suga C, Hayes DL, Hyberger LK, Lloyd MA. Is there an adverse outcome from abandoned pacing leads? J Interv Card Electrophysiol. 2000;4:493-9.

603. Franceschi F, Thuny F, Giorgi R, et al. Incidence, risk factors, and outcome of traumatic tricuspid regurgitation after percutaneous ventricular lead removal. J Am Coll Cardiol. 2009;53:2168-74.

604. Atallah J, Erickson CC, Cecchin F, et al. A multi-institutional study of implantable defibrillator lead performance in children and young adults: Results of the pediatric lead extractability and survival evaluation (PLEASE) study. Circulation. 2013;127: 2393-402.